Literature DB >> 8614503

Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway.

C F Lippa1, A M Saunders, T W Smith, J M Swearer, D A Drachman, B Ghetti, L Nee, D Pulaski-Salo, D Dickson, Y Robitaille, C Bergeron, B Crain, M D Benson, M Farlow, B T Hyman, S P George-Hyslop, A D Roses, D A Pollen.   

Abstract

Whether all etiologic forms of Alzheimer's disease (AD) share a final common pathway is a major issue. We determined the severity and regional distribution of neuronal loss, amyloid plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs), and calculated the ratio of neuronal loss to NPs and NFTs in brains of 19 familial AD (FAD) patients with linkage to chromosome 14, six AD patients with mutations of chromosome 21 (codon 717 of the beta-amyloid percursor protein gene), and 11 sporadic AD (SAD) patients. There was no difference in the pattern of distribution of the various pathologic features or in the ratio of neuronal loss to NPs or NFTs in any AD group. However, FAD groups could be distinguished from SAD by the greater severity and the lack of influence of apolipoprotein E genotype on pathology. These differences may reflect differences in age at onset rather than different etiopathologic mechanisms. The similarity of pathologic findings in the different AD groups provides evidence for a final common pathophysiologic pathway in AD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8614503     DOI: 10.1212/wnl.46.2.406

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

Review 1.  The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review.

Authors:  R A Nixon; A M Cataldo; P M Mathews
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 2.  The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.

Authors:  Paul S Aisen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  The genetics and neuropathology of Alzheimer's disease.

Authors:  Gerard D Schellenberg; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2012-05-23       Impact factor: 17.088

4.  Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice.

Authors:  V Askanas; W K Engel
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

5.  Stable size distribution of amyloid plaques over the course of Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Matthew L Mielke; Alona Muzitansky; Teresa Gómez-Isla; John H Growdon; Brian J Bacskai; Rebecca A Betensky; Matthew P Frosch; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2012-08       Impact factor: 3.685

6.  Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.

Authors:  Yakeel T Quiroz; Reisa A Sperling; Daniel J Norton; Ana Baena; Joseph F Arboleda-Velasquez; Danielle Cosio; Aaron Schultz; Molly Lapoint; Edmarie Guzman-Velez; John B Miller; Leo A Kim; Kewei Chen; Pierre N Tariot; Francisco Lopera; Eric M Reiman; Keith A Johnson
Journal:  JAMA Neurol       Date:  2018-05-01       Impact factor: 18.302

7.  Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.

Authors:  William E Klunk
Journal:  Arch Neurol       Date:  2008-10

8.  Presenilin/gamma-Secretase and Inflammation.

Authors:  Carlos A Saura
Journal:  Front Aging Neurosci       Date:  2010-05-18       Impact factor: 5.750

9.  Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.

Authors:  Gregory S Day; Erik S Musiek; Catherine M Roe; Joanne Norton; Alison M Goate; Carlos Cruchaga; Nigel J Cairns; John C Morris
Journal:  JAMA Neurol       Date:  2016-09-01       Impact factor: 18.302

Review 10.  Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.

Authors:  Randall J Bateman; William E Klunk
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.